Adapalene, an approved drug clinically used in the therapy of acne vulgaris, could selectively inhibit the activity of GOT1 in a non-competitive manner and further suppress the proliferation of ovarian cancer ES-2 cells (86). This evidence concerns the gene GOT1 and ovarian cancer.